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Abstract 
A vaccine is a biological preparation that actively stimulates adaptive immunity to protect against 
a target disease. Prophylactic vaccination is the most effective method of preventing infectious 
diseases and may be applied to the prevention or treatment of other non-communicable diseases 
(e.g. Cancer, Alzheimer’s). Herd immunity due to vaccination is largely responsible for the 
worldwide eradication of smallpox and containment of other diseases such as polio (type 2), 
measles, tetanus, and pertussis (whooping cough) [1]. Traditional vaccines consist of live-
attenuated forms (e.g. Bacillus Calmette–Guérin vaccine, typhoid vaccine, measles-mumps-
rubella vaccines) or whole cell preparations of the target infectious agent (e.g., whole cell 
pertussis vaccine). Biotechnology advances have enabled newer vaccines to be based on the 
rational design of recombinant antigens containing highly purified components with excellent 
safety profiles. Conversely, the immunogenicity of such well-defined vaccine antigens may be 
lower compared to vaccines comprised of live attenuated or inactivated pathogen preparations. 
Candidate vaccines consisting of purified subunits or proteins from bacteria or viruses are less 
immunogenic and require the use of adjuvants to generate a strong immune response to the 
administered antigen.  To increase vaccine efficacy, there is a need to develop more potent and 
safer adjuvants or immunostimulators. In my masters’ project, I have explored the effects of a 
novel molecular adjuvant on the immune responses to a traditional tetanus-diphtheria-pertussis 
vaccine (TDaP).  
 
1. Introduction- 
1.1 Adjuvants  
Adjuvants are defined as compounds that enhance and/or shape antigen-specific immune 
responses after vaccination [2]. The immune system has evolved to recognize antigenic moieties 
called pathogen-associated molecular patterns (PAMP). Adjuvants mimic the physical-chemical 
features and mechanisms of such moieties. Currently marketed adjuvants consist of mineral salts, 
emulsions, liposomes and virosomes, which provide a delivery system that improves antigen 
presentation to professional antigen presenting cells (e.g., macrophages) displaying MHC I and 
II receptors. Use of such adjuvants can control the release of the antigen, and modulates the 
quantity and quality of the immune response [2]. Another class of adjuvants includes 
immunostimulants, which target specific receptors or pathways involved in activation of the 
immune response against antigens. For example, a variety of adjuvants are ligands to PAMP 
called toll-like receptors (TLR). These compounds modulate cytokine production, activation of 
MHCI and II receptors, co-stimulatory signals involved in activation of B and T cell lymphocytes, 
and downstream intracellular signaling pathways [3].  Table 1 provides an overview of current 
adjuvants. 
 Table 1. Overview of approved and under development adjuvants. 
Adjuvant Type Examples Composition Target or 
formulation 
Mineral salts and 
organic compounds 
Aluminum Aluminum phosphate and 
aluminum hydroxide. 
 
TDaP, anthrax 
vaccine, 
poliomyelitis vaccine. 
Veterinary vaccines 
for avian infectious 
bronchitis virus, 
clostridium botulinum, 
bacteroides nodosus. 
AS03 (Adjuvant 
System 03) 
Squalene, α-tocopherol, 
polysorbate 80. 
Seasonal influenza 
virus vaccine. 
MF59 Oil-in-water squalene based Influenza vaccine in 
65+ years old. 
AF03 Oil-in-water squalene based Pandemic influenza 
vaccine. 
TLR based Adjuvants Adjuvant System AS04 Aluminum hydroxide and 
monophosphoryl lipid A 
(MPLA, TLR4 Agonist) 
Hepatitis B virus 
(HBV), Human 
papillomavirus (HPV). 
CpG Short single-stranded 
synthetic DNA molecules, 
TLR9 ligand. 
Hepatitis B virus.  
AS02* Oil / water emulsion, of 
monophosphoryl lipid A 
(MPL) and QS21, an extract 
from plant Quillaria 
saponaria.  
Malaria vaccine.    
AS15** Liposomal formulation of 
TLR4 and TLR9 agonists. 
Prostate cancer, 
Breast cancer. 
Monophosphoryl Lipid 
A (MPLA) 
TLR4 agonist Preclinical studies in 
chronic myelogenous 
leukemia, breast 
cancer vaccines.     
AS01*** Saponin QS-21 and MPLA 
based liposomal adjuvant 
Malaria vaccine. 
Particle-based 
Adjuvants 
Virosomes Virus derived protein based 
liposome 
Hepatitis B virus  
Liposomes  Hepatitis A virus 
 
* Phase 1 clinical trial for malaria concluded in 2015. Study sponsored by U.S. Army Medical 
Research.  
* *Currently in a European Phase I/II safety and efficacy study in prostate cancer patients. Also, 
a Phase II trial of the recombinant Her2 protein with AS15 adjuvant is currently underway 
*** On 17 November 2016, WHO has announced that malaria vaccine, RTS, S/AS01 would be 
rolled out in pilot projects in 3 countries in sub-Saharan Africa. 
 
1.2 Need for newer adjuvants 
Traditional adjuvants such as alum, aluminum phosphate, and aluminum hydroxide have been 
widely used.  Although they have several advantages, they are far from ideal. Some of the 
limitations to alum-based adjuvants include the production of IgE antibodies leading to 
hypersensitivity reactions, inability to elicit cell-mediated immunity, local reactions, poor 
immunogenicity [3]. Recently approved adjuvants have shown promising clinical efficacy but their 
use is limited by toxicity (e.g., AS03), side effects or proprietary restrictions (e.g., CpG and MF59 
by Pfizer and Novartis respectively). Thus, there is a need for the development of more potent 
and safer adjuvants or immunomodulators. Additionally, a broad range of adjuvant options will 
benefit at-risk or sensitive populations including pregnant women, elderly, infants, and 
immunocompromised individuals. For instance, AS01 used in phase 3 clinical trials of a malaria 
vaccine showed 95% efficacy in children 5–17 months old, but showed efficacy only in 16% of 
infants aged 6–12 weeks [4]. Adjuvants may show different efficacy when administered in different 
formulations or paired with different vaccines. Adjuvants cannot be approved as standalone 
formulations, but regulatory agencies will evaluate specific adjuvant/antigen formulations. This 
implies that the development of an adjuvant is strictly related to the antigen present in the specific 
formulation and may be affected by guidelines of specific regulatory agencies (e.g., FDA vs. 
EMA). 
1.3 A cytokine-based immunomodulator as a novel molecular adjuvant. 
Cytokines are known to modulate immune response via regulation of B and T cell lymphocytes, 
antibody production or by triggering an inflammatory response. Among cytokines, interleukins (IL) 
are known to regulate pathways leading to antibody production against pathogens or other 
antigens, including small molecules and proteins. Among interleukins, IL-4, IL-6 and IL-21 support 
B cell activation processes including isotype switch, affinity maturation, and clonal selection which 
are key events involved in the formation of long lived high affinity antibody secreting B cells and 
memory B cells [6].  Thus, an agent that modulates interleukin signaling can be used as a molecular 
adjuvant to optimize long term immune responses against challenging targets or specific patient 
population subsets.  
 
1.4 Cellular events involved in antibody responses after immunization. 
After immunization, the antigen binds to the B cell receptor (BCR) displayed on the surface of B 
cells. Binding to the BCR activates various B cell processes leading to B cell differentiation in 
specialized subsets, which have diverse roles in adaptive immunity. Critical to antibody production 
is the T cell dependent B cell activation in germinal centers (GC) of lymph nodes and spleen 
where antigen-specific B cells, aided by T follicular helper (Tfh) cells, differentiate into long lived 
antibody secreting B cells and switched immunoglobulin memory B cells [6,7].  
GC formation is a complex and a poorly understood process, which is modulated by interleukins, 
co-stimulatory molecules, and downstream signaling pathways. Recent literature suggests that 
biologics or small molecules targeting these signaling pathways can be exploited to optimize 
humoral or cellular responses against different targets. 
1.4.a. Germinal center formation  
 Activated B cells can differentiate along many pathways. Commitment to a specific pathway is 
dependent upon interleukins and co-stimulatory molecules such as ICOSL, CD40L, and CD28 [8]. 
Binding of some interleukins to interleukin receptors on B or T cells activates the Janus kinase/ 
Signal Transducer and Activator of Transcription (JAK/STAT) pathway, which control downstream 
transcription factors.  The main pathways are outlined in the figure below:  
 
 
Figure 1. Major pathways of B cell activation. Activation of the B-lymphocyte-induced maturation 
protein (blimp-1), a transcriptional regulator is characteristic of formation of short lived antibody 
secreting plasma cells [9]. Activation of B-cell lymphoma 6 protein (bcl-6), a transcriptional 
regulator results in formation of GC B and Tfh cells [9,10,11].  
 
A vaccine response involves binding of interleukins like IL-4 and IL-21 which leads to GC 
formation, isotype switch and affinity maturation via activation of the bcl-6 pathway (or down-
regulation of the blimp-1 pathway) to generate long lived antigen specific antibodies [12,13]. Thus, 
any agent that prolongs the presence of interleukins like IL-4 induces GC formation. My project 
tested the hypothesis that the vaccine responses can be improved by the means of an anti-IL-4 
monoclonal antibody that binds and extends the half-life of IL-4. To test this hypothesis, my 
studies involved the use of an adult tetanus, diphtheria, acellular pertussis vaccine (BOOSTRIX 
from GlaxoSmithKline).  
 
 
 2. Experimental Design  
Male BALB/c mice (Harlan Laboratories, Madison, WI) were housed with a 12hr light /12 hr. dark 
cycle, and fed ad libitum. Mice were divided into 2 cohorts and immunized with TDaP plus anti-
IL-4 mAb or saline. The immunization schedule was performed as shown in Table 2.  In this 
experiment, BALB/c mice (n=14 / group) received either TDaP or TDaP plus anti-IL-4 mAb. After 
immunization, antigen-specific serum IgG titers were measured by ELISA using tetanus toxoid 
(TT) or cross-reactive material 197 (CRM197) from diphtheria as coating antigens. 
 
Table 2- Experimental protocol 
Event time Immunization & Experimental Protocol 
 
Day -3 Test mice were injected with an anti-IL-4 mAb (0.5mg/mice, i.p., 0.5ml injection 
volume). Control mice received volume-matched saline injections.  
Day 0 Test and control mice were injected with TDaP vaccine (25µl, s.c.). 
Day 1 Test mice were injected with an anti-IL-4 mAb (0.5mg/mice, i.p., 0.5ml injection 
volume). Control mice received volume-matched saline injections.  
Day 14 Blood was collected by facial vein puncture to measure antibody by ELISA. 
Test and control mice were injected with TDaP vaccine (25µl, s.c.). 
Day 28 Blood was collected by facial vein puncture to measure antibody by ELISA. 
Test and control mice were injected with TDaP vaccine (25µl, s.c.). 
Day 42 Blood was collected by facial vein puncture to measure antibody by ELISA. 
 
 
3. Materials and Methods. 
 
3.1 ELISA for tetanus toxoid- and diphtheria-specific serum IgG antibody titers. 
ELISA was performed to quantify antigen-specific IgG titers in immunized mice. To detect, TT and 
CRM197-specific IgG titers, ELISA plates were coated with 5ng/well of TT or CRM197. Chicken 
ovalbumin (OVA) was used as a control antigen. Coating of TT and CRM197 was done with 
carbonate buffer at pH 9.6 and blocked with 1% gelatin. Primary antibodies were incubated with 
anti-mouse IgG antibodies (Jackson ImmunoResearch Laboratories, West Grove, PA) to 
measure TT or CRM197-specific serum IgG antibody titers. OPD (o-phenylenediamine 
dihydrochloride) was used as a water-soluble substrate for horseradish peroxidase (HRP). 
Absorbance was measured at 492nm. 
 
Figure 2-Diagram of the ELISA assay  
 
 
 
 
 
 
 
3.2 Development of sensitive reagents to detect antibodies specific for TT and CRM197 in 
immunoassays: biotinylation.  
  
Streptavidin (SA) and avidin are proteins that bind to biotin with high affinity. Streptavidin 
conjugated to fluorophores, enzymes, or fluorescent proteins (e.g., phycoerythrin, PE) are used 
to detect biotinylated molecules in standard immunoassays such as ELISA or flow cytometry used 
in pre-clinical or clinical setting. During my laboratory rotation, I explored the development of 
conjugates consisting of antigen-biotin-SA-PE to detect antigen-specific serum IgG antibodies 
and B cells in mouse and human samples. 
Specifically, these reagents will be used to isolate antigen-specific B cells from spleen, lymph 
nodes, and blood samples. In these assays, samples are first incubated with antigen-biotin-SA-
PE conjugates, and then antigen-specific B cells are isolated using anti-PE magnetic beads and 
magnetized columns. Using flow cytometry, it is possible to further characterize the number of 
antigen-specific B cell populations displaying a specific phenotype. For instance, after 
immunization, this method allows to analyze whether a specific vaccine formulation induces 
memory B cells or plasma cells.  
In order to develop a reliable biotinylation protocol, my efforts focused on model antigens OVA 
and bovine serum albumin (BSA). OVA and BSA were biotinylated using N-
hydroxysuccinimidobiotin (NHS-biotin) provided as a kit (EZ-Link™ NHS-Biotin). Tested 
biotinylation conditions included antigen: biotin molar ratios of 1:1, 1:2, 1:5, 1:15, 1:20, and 1:25. 
Antigens were dissolved in distilled water and NHS-biotin was dissolved in dimethylformamide 
(DMF). Biotinylation was verified using Matrix Assisted Laser Desorption Ionization Time-of-Flight 
(MALDI TOF) by comparing the molecular weight of the native and biotinylated proteins. Samples 
were prepared through zip tipping using Millipore ZipTips 0.6ml C4 resin to remove salts and other 
small molecules, which may interfere with MALDI-TOF. The samples were hydrated using 10μl of 
wetting solution (1:1 acetonitrile (ACN): distilled water, 0.1% trifluoroacetic acid (TFA)) and 10μl 
of wash solution (0.1% TFA in distilled water). The samples were then eluted with a solution of 
3:1 ACN: distilled water, 0.1%TFA. In the end, 1μl of sample and 1μl of matrix solution containing 
5% sinapic acid were mixed and loaded onto the MALDI detection plate for analysis. 
 
3.3 Statistical Analysis 
Mean IgG titers were compared by unpaired T-test with 95% confidence interval by means of 
Graph Pad Prism 6 software.  
 
4. Results-  
4.1 Production of antigen-specific serum IgG antibodies  
Serum IgG antibody titers for  CRM197 specific IgG titers increased till day 28 and then dropped 
on day 42 (Figure 3B). In contrast, TT-specific IgG antibody titers showed a trend towards 
decrease after day 14(Figure 3A). The use of anti-IL-4 mAb as an adjuvant elicited significantly 
higher serum IgG titers for both tetanus toxoid and CRM197 on day 28 and 42. (Figure 3A & 3B).  
Figure 3A- Analysis of TT-specific serum antibody titers after immunization. 
 
 
 
 Figure 3B- Analysis of CRM197-specific serum IgG antibody titers after immunization. 
 
 
 
 
4.2 Biotinylation – 
Haptenization ratio is the number of biotin molecules conjugated to a hapten and can be 
calculated by the formula- 
 (Molecular weight of hapten NHS conjugate) – (Molecular weight of hapten)  
________________________________________________________________________ 
(Molecular weight of NHS biotin (341.38 Da))  
 
The haptenization ratio correlated with the molar excess of biotin used in the biotinylation for 
haptens BSA and OVA (Figure 4B). Biotinylation of TT and CRM197 could not be carried out. The 
reason could be the unavailability of exposed amino groups in these large proteins for NHS to 
react and form stable amide bonds or alternatively, challenges in the detection of their molecular 
weight by MALDI-TOF. 
 
 
 
 
 
  
 
 
 
Figure 4A-MALDI reports  
 
 
Figure 4B- Correlation between haptenization ratio and molar excess of biotin 
 
 
5. Discussion and Conclusions  
The importance of interleukin 4 in the antibody response of animals immunized with alum 
adsorbed antigen has been highlighted in several studies [14].  My results show that blocking IL-4 
signaling impacts vaccine response in mice. However further studies with this monoclonal 
antibody are needed. If successful, the mAb could be explored for clinical use as a vaccine 
adjuvant in traditional and newer vaccines. The presumed mechanism of anti-IL-4 mAb is through 
prolongation of IL-4 half-life by directly binding the endogenous IL-4 and slowly release it over 
time. Overproduction of IL-4 is associated with allergies [15]. Thus, toxicology studies should be 
conducted to assess the safety of this reagent. 
Regulatory guidelines in the US and Europe require pre-clinical data such as proof of efficacy, 
pharmacokinetic parameters, and toxicity of adjuvant alone before a human trial [16,17]. Preliminary 
studies should establish the effect of the adjuvant on the immunological responses to the 
antigen(s). For instance, future studies with compounds targeting IL-4 signaling could include 
analysis of vaccine-specific B cells and T cell responses by means of flow cytometry, optimization 
of dose and determination of its pharmacokinetic parameters. 
Adjuvant and formulation selection may be based on several parameters, including the physical 
and chemical natures of the vaccine antigen, type of immune response desired, age of the target 
population and route of vaccine administration. The desired qualities of each vaccine may 
necessitate adjuvants with specific properties. Indeed, the selection of the wrong adjuvant may 
render a vaccine antigen inadequate. Thus, vaccine antigen selection must consider adjuvant 
selection to avoid discarding potentially effective vaccine antigen candidates. 
In the development of new adjuvant vaccines, it will be important to focus on clear unmet needs 
to establish a favorable benefit-to-risk ratio. Moreover, to engender positive public perception, 
rigorous clinical and post-marketing testing will be required to identify potential safety issues, as 
well as the mechanisms involved to guide subsequent vaccine development projects. 
Understanding the limitations of preclinical models will help avoid surprises in the clinic. 
Furthermore, understanding of the proposed mechanisms of action of existing adjuvants must 
continue to be refined. These aspects must play vital parts to realize all the potential benefits that 
adjuvants offer. 
In conclusion alum-based vaccines were originally licensed more than 70 years ago. However, it 
remains unclear exactly how aluminum salts work as adjuvants. Moving beyond the use of alum, 
other approved adjuvants in human vaccines include MF59, AS03 and AS04. Future vaccines will 
contain recombinant protein antigens, purified synthetic adjuvants and delivery systems designed 
to ensure that the antigen is targeted efficiently to antigen presenting cells and that activates 
specific components of the adaptive immune system.  
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